Livongo Health has completed a $44.5 million Series C financing round from both new and existing investors. The former group includes Merck Global Health Innovation Fund, Cowen Private Investments, Sapphire Ventures, Zaffre Investments (the investment arm of Blue Cross Blue Shield of Massachusetts) and Wanxiang America Corporation; while the latter includes General Catalyst, Kleiner Perkins Caufield & Byers (KPCB), DFJ, and 7wire Ventures.

Livongo Health’s diabetes management solution has been adopted by the country’s largest self-insured employers, payers, and healthcare providers; and the new funds will be used to add new clients, accelerate the launch of new products and services, and to expand into new market segments.

“We are excited by the demand for our solution, which combines the latest technology, data science, and coaching to empower people with diabetes to live a better life,” Glen Tullman, CEO of Livongo Health, said in a statement. “The most important challenge to address in healthcare today is how we manage chronic disease, and the status quo simply isn’t working. Livongo Health’s platform delivers real-time, personalized support in context, when and where it’s needed.”

Earlier this year, mHealth Spot reported about Healthstat’s intention to deploy Livongo for Diabetes throughout its onsite clinic network. Before that, the company has partnered with Mount Sinai and Cerner.

Livongo Health was founded in 2014 and to date it has raised $77.5 million.